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INTRODUCTION
Auto- or alloimmune-mediated hemolytic anemia occurs in
3–9% of allogeneic hematopoietic stem cell transplant (HSCT)
patients [1,2]. In autoimmune hemolysis, donor-derived antibodies
react against donor red blood cell (RBC) antigens, while in
alloimmune hemolysis, RBC antigen incompatibility between
donor and recipient gives rise to reactive alloantibodies [3]. The
clinical course depends on whether the antibodies are auto or allo in
origin and ranges from mild to life-threatening [3]. We describe a
pediatric HSCT patient with refractory delayed alloimmune
hemolytic anemia due to major ABO incompatibility that was
further complicated by immune-mediated neutropenia and throm-
bocytopenia. He was successfully treated with Campath-1H
following poor responses to multiple therapeutic agents.
CASE REPORT
A 6-year-old male with X-linked adrenoleukodystrophy (ALD)
was treated with a 5/6 mismatched, major ABO incompatible,
unrelated cord blood (UCB) transplantation. The patient’s ABO and
HLA type were O-; A 24,68 B 40,44 DRB 0401,0701. The donor
unit typed as group Aþwith a class I disparity at A locus: A 24,32 B
40,44DRB0401,0701. In preparation for the transplant, he received
busulfan, cyclophosphamide, and anti-thymocyte globulin. A total
of 4.6 107 nucleated cells/kg (1.8 105 CD34þ cells/kg) were
infused. Cyclosporine andmethylprednisolonewere given for graft-
versus-host disease (GVHD) prophylaxis. The patient engrafted
neutrophils (absolute neutrophil count, ANC>500/mm3) on day 20.
He became independent of packed red blood cells (PRBC)
transfusions (hemoglobin >8 g/dl) on day 56 and of platelet
transfusions (platelets >40,000/mm3) on day 70. Peripheral blood
PCR of microsatellite markers showed full donor engraftment on
day 21.
Six months post-transplantation, the patient developed hemo-
lytic anemia with a sudden decrease in hemoglobin to 7.1 g/dl from
9.3 g/dl and a corresponding increase in reticulocyte count (6.42%),
LDH (306 IU/L, normal ranges 140–280 IU/L), and indirect
bilirubin (1.4 mg/dl) (Fig. 1). Direct antiglobulin testing (DAT)
revealed 3þ IgG anti-A antibodies in the plasma and eluate,
confirming the hemolysis was immune-mediated. Repeat engraft-
ment analysis of peripheral blood demonstrated both donor (94%)
and recipient (6%) cells.
The patient was started on methylprednisolone (2 mg/kg/day)
and the hemolysis initially improved. Two months later, while still
receiving methylprednisolone (0.5 mg/kg/day), the hemoglobin
declined once again and the reticulocyte count, LDH, and indirect
bilirubin rose, prompting re-escalation of the methylprednisolone
dose and initiation of rituximab therapy (375 mg/m2 IV weekly for
four weeks 2). The patient’s clinical course deteriorated with
declining neutrophil and platelet counts over the next three months
(Fig. 2). He required cytokine (erythropoietin, G-CSF, and GM-
CSF) support and 1–2 transfusions of PRBC (groupO) and platelets
(group A) per week. A bone marrow biopsy demonstrated normal
cellularity with erythroid hypoplasia, granulocytic predominance,
and adequate megakaryocytes. Evaluation for anti-neutrophil and
anti-platelet antibodies was not undertaken. The patient then
received pentostatin (4 mg/m2 IV every two weeks 2) without
improvement. Nine months after the onset of hemolysis, Campath-
1H (alemtuzumab, 15 mg/day IV three times per week 1, Berlex
Oncology, Montville, NJ) was administered. The patient tolerated
Campath-1H therapy without adverse events. During the period of
intensive immunosuppression the patient received pentamidine,
fluconazole, acyclovir, and valganciclovir for infection prophylaxis.
Eight weeks after Campath-1H administration, the patient’s
hemoglobin increased to 8 g/dl and platelet count increased to a
value above 40,000/mm3 without support. His ANC rose above
1,000/mm3 without G-CSF or GM-CSF supplementation 18 weeks
later. The patient’s immunosuppressive medications were
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Fig. 1. Biochemical and hematologic evidence of hemolysis is demonstrated with a rising lactic dehydrogenase (LDH) level, falling hemoglobin
(Hgb) level, and positive direct antiglobulin testing (DAT). The patient was treated with several medications including rituximab, intravenous
immunoglobulins (IVIG), pentostatin, cyclosporine, and methylprednisolone without response. Erythropoietin and packed red blood cell (PRBC)
transfusions were also administered. After one course of Campath-1H therapy, the patient’s hemoglobin improved and LDH normalized.
Interestingly, the DAT remains positive despite a normal Hgb level.
Fig. 2. The patient also developed immune-mediated thrombocytopenia and neutropenia. Platelets were transfused and granulocyte colony
stimulating factor (G-CSF) and granulocyte-monocyte stimulating factor (GM-CSF) were administered for low absolute neutrophil count (ANC)
levels. Both cytopenias resolved after Campath-1H therapy. Platelet and neutrophil values represented in the graph are pre-transfusion or pre-
cytokine values.
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discontinued with no signs of GVHD. He has maintained a
hemoglobin >12 g/dl, ANC >2,000/mm3, and platelet count
>150,000/mm3 (Figs. 1 and 2) 22 months after Campath-1H
treatment.
DISCUSSION
Major ABO incompatible HSCT is characterized by recipient-
derived ABO antibodies directed against donor RBC antigens.
These anti-donor isohemagglutinins can cause immunohematologic
complications including hemolysis, delayed erythrocyte engraft-
ment, and pureRBCaplasia [4].We present a patientwho developed
delayed alloimmune hemolytic anemia following mismatched
major ABO incompatible UCB transplantation for X-linked ALD.
The patient’s pre-transplantation blood group was O while the
donor cord unit was Aþ. Detection of mixed chimerism and anti-A
RBC antibodies suggested residual recipient lymphocytes produced
anti-A antibodies responsible for hemolysis. Isohemagglutinins
originating from enduring recipient lymphocytes have been
previously reported [3]. We speculate our patient’s relative immune
competence in combination with a cyclosporine-based GVHD
prophylaxis regimen predisposed to proliferation of recipient
lymphocytes and generation of isohemagglutinins. O’Brien et al.
showed that patients transplanted for metabolic disorders were
4.2 times more likely to experience autoimmune hemolysis in
comparison with patients transplanted for malignancies. Patients
with non-malignant disorders have not been exposed to cytotoxic or
immunosuppressive therapy and are relatively immune competent
whichmay contribute to immune hemolysis [2].Moreover, although
cyclosporine is immunosuppressive, it permits recipient lympho-
cyte proliferation and isohemagglutinin expansion; studies have
shown that patients who receive cyclosporine GVHD prophylaxis
are at increased risk of alloimmune hemolysis [1,3].
Our patient also developed neutropenia and thrombocytopenia.
A bone marrow examination showed normal granulocyte and
megakaryocyte numbers with maturation suggesting the low blood
counts were immune-mediated. It is unclear whether anti-platelet
and anti-neutrophil antibodies were present or were donor or
recipient in origin. Based on studies in autoimmune hemolytic
anemia associated with immune thrombocytopenia and/or neutro-
penia (Evans syndrome), the causative antibodies are directed
against specific RBC, platelet, or neutrophil antigens and do not
cross react. Decreased CD4 T-lymphocytes, increased CD8 T-
lymphocytes, and a markedly decreased CD4:CD8 ratio in patients
with Evans syndrome suggests that the disorder may be a result of
abnormal T-cell regulation [5]. Furthermore, recent findings of poor
clinical efficacy of rituximab for the treatment of autoimmune
neutropenia and pure red cell aplasia in comparison with historical
responses to Campath-1H implies a critical role for T-cells in
controlling the expansion of autoreactive B-cells [6]. Response
to Campath-1H therapy supports a contributory if not causal role for
T-cell dysregulation in our patient’s cytopenias.
Campath-1H is amonoclonal antibody specific for CD52 surface
glycoprotein expressed on B- and T-lymphocytes [7]. Binding of
Campath-1H to CD52 antigen activates antibody-dependent cell-
mediated lysis of cells and profound lymphopenia [8]. While B-
lymphocytes recover by six months [7], full recovery of CD4 and
CD8 T-lymphocytes can take more than 12 months [8]. Because of
these properties, Campath-1H has been used for treatment of
immune-mediated disorders including autoimmune cytopenias.
Willis et al. administered Campath-1H to 21 patients with refractory
autoimmune hemolytic anemia, pure red cell aplasia, immune
thrombocytopenia purpura, autoimmine hemolytic anemia with
thrombocytopenia, or autoimmune pancytopenia and found a 71%
initial response rate and a 29% sustained response rate; concluding
that Campath-1H is an alternative therapeutic option for resistant
autoimmune cytopenias [7].
Complex immunohematological events can complicate HSCT.
Imbalances in reactive and regulatory donor and recipient
lymphocytes may underlie our patient’s cytopenias. Successful
treatment of immune-mediated hemolytic anemia, neutropenia, and
thrombocytopenia with Campath-1H in our patient suggests that
this antibody may terminate pathologic immune processes. As
T-lymphocytes are major targets of Campath-1H, our case also
highlights an important role for T-lymphocytes in the pathophysiol-
ogy of immune-mediated cytopenias.
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